Thyroid Cancer Clinical Trials
Here are the 6 most popular medical studies for thyroid cancer
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Tyrosine Kinase Inhibitor
Vandetanib for Advanced Medullary Thyroid Cancer
This trial is testing two different doses of vandetanib for patients with medullary thyroid cancer. The goal is to see how well each dose affects the cancer and what side effects result from each.
Popular filter options for thyroid cancer trials
Thyroid Gland Carcinoma Clinical Trials
View 70 Thyroid Gland Carcinoma medical studies.
Tyrosine Kinase Inhibitor
Pralsetinib for Thyroid Cancer and Non-Small Cell Lung Cancer
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Thyroid Nodule Clinical Trials
View 65 Thyroid Nodule medical studies.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Metastatic Thyroid Cancer Clinical Trials
View 97 metastatic thyroid cancer medical studies.
Tyrosine Kinase Inhibitor
Pralsetinib for Thyroid Cancer and Non-Small Cell Lung Cancer
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
Kinase Inhibitor
Sorafenib Tosylate for Medullary Thyroid Cancer
This trial looks at how well a drug called sorafenib tosylate works in treating patients with thyroid cancer that has spread or returned. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
mTOR inhibitor
Bevacizumab + Temsirolimus + Valproic Acid + Cetuximab for Malignancy
This trial is studying the best dose and side effects of bevacizumab and temsirolimus when given alone or with valproic acid or cetuximab to treat patients with a non-cancerous malignancy.
BRAF Positive Clinical Trials
View 16 BRAF positive medical studies.
Tyrosine Kinase Inhibitor
Pralsetinib for Thyroid Cancer and Non-Small Cell Lung Cancer
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
MEK Inhibitor
Selumetinib + Olaparib for Solid Tumors
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
RET Positive Clinical Trials
View 8 RET positive medical studies.
Tyrosine Kinase Inhibitor
Pralsetinib for Thyroid Cancer and Non-Small Cell Lung Cancer
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
Kinase Inhibitor
Sorafenib Tosylate for Medullary Thyroid Cancer
This trial looks at how well a drug called sorafenib tosylate works in treating patients with thyroid cancer that has spread or returned. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Tyrosine Kinase Inhibitor
Selpercatinib + Cabozantinib + Vandetanib for RET-Mutant Medullary Thyroid Cancer
This trial is testing a new drug to see if it's more effective and safe than the current standard treatment for people with a certain type of thyroid cancer.
Tyrosine Kinase Inhibitor
Pralsetinib for Medullary Thyroid Cancer
This trial will compare the effectiveness of a new drug, pralsetinib, to the standard of care (SOC) treatment for people with a specific type of thyroid cancer. Participants will be randomly assigned to either the new drug or the SOC treatment. If their disease progresses while taking the SOC treatment, they will be offered the new drug.
Phase 3 Thyroid Cancer Clinical Trials
View 97 phase 3 thyroid cancer medical studies.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Tyrosine Kinase Inhibitor
Selpercatinib + Cabozantinib + Vandetanib for RET-Mutant Medullary Thyroid Cancer
This trial is testing a new drug to see if it's more effective and safe than the current standard treatment for people with a certain type of thyroid cancer.
Kinase Inhibitor
Dabrafenib + Trametinib for Differentiated Thyroid Cancer
This trial is testing whether the combination of dabrafenib and trametinib is more effective than placebo for treating patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
Tyrosine Kinase Inhibitor
Pralsetinib for Medullary Thyroid Cancer
This trial will compare the effectiveness of a new drug, pralsetinib, to the standard of care (SOC) treatment for people with a specific type of thyroid cancer. Participants will be randomly assigned to either the new drug or the SOC treatment. If their disease progresses while taking the SOC treatment, they will be offered the new drug.
Thyroid Cancer Clinical Trials With No Placebo
View 97 thyroid cancer medical studies that do not have a placebo group.
Tyrosine Kinase Inhibitor
Pralsetinib for Thyroid Cancer and Non-Small Cell Lung Cancer
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
View More Thyroid Cancer Trials
See another 70 many medical studies focused on thyroid cancer.
Frequently Asked Questions
Introduction to thyroid cancer
What are the top hospitals conducting thyroid cancer research?
When it comes to cutting-edge clinical trials in the realm of thyroid cancer, several renowned hospitals are leading the way. In New York City, Memorial Sloan Kettering Cancer Center is revolutionizing research with an impressive 21 active thyroid cancer trials. While they have not conducted any previous studies specifically focused on this condition, their dedication to exploring new treatments offers hope for patients and sets the stage for groundbreaking discoveries. Similarly, M D Anderson Cancer Center in Houston boasts 17 ongoing trials dedicated to advancing our understanding and treatment options for thyroid cancer.
Moving along the East Coast, Dana-Farber Cancer Institute in Boston is also making significant contributions with eight active clinical trials aimed at improving outcomes for those affected by thyroid cancer. Although this institution has not previously conducted any specific thyroid cancer studies, their commitment to innovation positions them as a force within the field.
In Houston's University of Texas MD Anderson Cancer Center and Rochester's Mayo Clinic, both institutions have begun delving into the world of thyroid cancer research more recently. With seven ongoing trials each at these hospitals, they are actively investigating new avenues and potential breakthroughs that may shape future treatment approaches. Both centers initially embarked on their pioneering journeys into this particular type of trial in 2017.
These top hospitals stand as beacons of hope for individuals battling against thyroid cancer across different locations throughout America; all united by a common goal: finding more effective treatments while striving towards improved patient outcomes . Their relentless pursuit of knowledge and dedication to medical advancements offer promise that one day we will conquer this complex disease
Which are the best cities for thyroid cancer clinical trials?
Houston, Texas; New York, New York; Los Angeles, California; Boston, Massachusetts; and Philadelphia, Pennsylvania are among the best cities for thyroid cancer, Massachusetts; and Philadelphia, Pennsylvania are among the best cities for thyroid cancer clinical trials. These cities offer a significant number of active trials focused on investigating various treatments such as Pembrolizumab, cabozantinib, LOXO-292, pralsetinib (BLU-667), Vemurafenib, Nivolumab, and more. Through these trials, researchers aim to advance our understanding of thyroid cancer treatment options and potentially improve outcomes for patients facing this disease.
Which are the top treatments for thyroid cancer being explored in clinical trials?
Thyroid cancer research is rapidly advancing, with notable treatments emerging in current clinical trials. One such treatment is Vemurafenib, currently being explored in two active trials for thyroid cancer. Despite its recent entry into the scene in 2020, it has already shown promising potential with a total of two all-time clinical trials dedicated to this specific type of cancer. As researchers continue their diligent efforts, there is hope that Vemurafenib and other innovative treatments will pave the way towards improved outcomes for patients battling thyroid cancer.
What are the most recent clinical trials for thyroid cancer?
Recent clinical trials offer a beacon of hope for individuals battling thyroid cancer. Amongst the latest advancements is a Phase 2 trial aimed at patients with radioiodine-refractory, recurrent, and/or metastatic differentiated thyroid cancer (DTC). This study explores innovative treatment options to address this challenging subtype of thyroid cancer. Another trial focuses on DB-1202 Dose Expansion 3, which investigates potential therapeutic benefits in patients with thyroid cancer through both Phase 1 and Phase 2 stages. Additionally, a Phase 1 Dose Expansion trial showcases promising developments in the field by evaluating new approaches for treating thyroid cancer. These groundbreaking studies bring us closer to improved outcomes and enhanced care for those affected by this disease.
What thyroid cancer clinical trials were recently completed?
Recently completed clinical trials in the field of thyroid cancer have made significant strides towards advancing treatment options. Notably, a trial sponsored by the National Cancer Institute (NCI) investigated the efficacy of a novel targeted therapy and concluded successfully. The results are encouraging for patients with thyroidl Cancer Institute (NCI) investigated the efficacy of a novel targeted therapy and concluded successfully. The results are encouraging for patients with thyroid cancer as they offer potential avenues for improved management of this complex disease.